Effects of recombinant @entity1 @entity1307 on fibrinolytic system in XXXX on continuous ambulatory peritoneal dialysis.

@entity1 @entity3479 @entity2289 @entity1307
We studied @entity3479 ) and @entity2289 ( @entity2289 ) levels in plasma and peritoneal effluent in 10 @entity1 on continuous ambulatory peritoneal dialysis (CAPD) before, and 8 and 12 weeks after, treatment with recombinant @entity1 @entity1307 (rHuEPO). Plasma @entity3479 and @entity2289 levels were lower in @entity1 than in controls during the study. The plasma @entity3479 levels were increased by rHuEPO treatment. Although @entity2289 levels showed a tendency to increase in the early phase of rHuEPO treatment, they later returned to near baseline levels. Peritoneal effluent @entity3479 levels were decreased at week 8 of treatment, but returned to baseline levels at week 12. Peritoneal effluent @entity2289 levels were not changed by the rHuEPO treatment. No correlation was observed between levels of @entity3479 and @entity2289 in plasma and in peritoneal effluent. No correlation was seen between plasma @entity2289 levels and duration of CAPD. A significant negative correlation was found between the plasma @entity2289 levels and hemoglobin levels at week 8 and week 12. These results suggest that plasma @entity3479 levels can be increased by rHuEPO treatment, while plasma @entity2289 levels are associated with hemoglobin levels.
